Overview
NICE is unable to make a recommendation on crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older because Pfizer withdrew its evidence submission.
Last reviewed: 19 May 2021
Next review: We will review this decision if the company decides to make a submission.